Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2017-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Succinate of Solifenacin reduces the OverActive Bladder syndrome occurring during prostate irradiation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH

NCT02972268

Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia

COMPLETED PHASE3

Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia

NCT00771394

Benign Prostatic Hyperplasia Benign Prostatic Hypertrophy Overactive Bladder

COMPLETED PHASE4

Botulinum Toxin Injection With Prostate Brachytherapy

NCT00681148

Prostate Cancer Lower Urinary Tract Symptoms Radioactive Seed Implantation

WITHDRAWN PHASE2

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

NCT01454349

Benign Prostatic Hyperplasia

COMPLETED PHASE1/PHASE2

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia

NCT00889707

Benign Prostatic Hyperplasia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A multicenter Phase III, randomized, double-blinded, parallel group placebo-controlled study.

2 groups:

* Control arm = pts. with placebo
* Experimental arm = pts. with Solifenacin succinate 5 mg - Vesicare® All patients with an OAB sub-score using the USP scale greater to 5 during prostate cancer radiotherapy will be included, receiving either a placebo or Solifenacin succinate (5mg) for duration of 3 months.

The randomization will be stratified on the radiotherapy dose (1 to 40 Gy or 40 to 70/80 Gy).

Screening:

For all patients, OAB items of the USP scale will be completed before each standard weekly assessment during prostate radiotherapy. Patients who reach an OAB sub-score greater to 5 will be addressed to an urologist in order to confirm absence of Qmax \< 10ml/sec at initial assessment, or post-void residual urine \> 100 milliliter (ml).

Inclusion \& treatment:

A week at most after pre-screening, patients will be randomized to receive either Vesicare®-5mg or a placebo. In both study arms, the treatment should be continued for 3 months.

Follow-up:

The radiation oncologist will perform patients' follow-up for the study at the treatment initiation, 6 weeks and 3 months after start of the treatment (Vesicare or placebo).

The questionnaires for the evaluation of OAB syndrome, acute urinary toxicity and quality of life should be completed for each follow-up visit. The voiding diary will be completed during 3 days before (or if not, 3 days after) all the evaluation times.

An urologist will perform an uroflowmetry and a post-voiding echography (or a bladder scan) before initiation of the treatment, and after 6 weeks of treatment.

Statistics and sample size PATIENTS ENROLMENT 70 patients will be included (considering 66 patients completing the full study) within 3 recruitment centers

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Succinate of Solifenacin

1 tablet of 5 mg of succinate of Solifenacin will be administered each day for 3 months.

Group Type EXPERIMENTAL

Succinate of Solifenacin

Intervention Type DRUG

Placebo of Succinate of Solifenacin

1 tablet of placebo of succinate of solifenacin will be administered each day for 3 months.

Group Type PLACEBO_COMPARATOR

Placebo of Succinate of Solifenacin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Succinate of Solifenacin

Intervention Type DRUG

Placebo of Succinate of Solifenacin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Prostate adenocarcinoma (histological confirmation),
* Indication for prostate cancer radiotherapy (standard schema with a total dose from 70 to 80 Gray (GY)),
* Patient affiliation to the French Social Security System,
* Patient information and written informed consent,
* Patient complaining of urinary symptoms during radiotherapy,
* Occurrence of OverActive Bladder (OAB) subscore with the Urinary Symptom Profile (USP) scale greater or equal to 5.

Exclusion Criteria

* Prostate irradiation contraindication
* History of bladder or prostate surgery,
* History of of pelvic radiotherapy,
* Individual deprived of liberty or placed Under the authority of a tutor,
* Age \< 18 years,
* Flowmetry Qmax \< 10ml/s and/or post-void residual urine \> 100 ml (during urology preinclusion visit)
* Previous known OAB
* Patients treated with non-authorized drugs,
* Patients treated with anticholinergic or cholinesterase inhibitors within 12 months before irradiation,
* Patients treated with anticholinergic during and weeks following irradiation and before Succinate of Solifenacin treatment start,
* Patients treated with botulinum toxin within 9 months before screening,
* Patients treated with alpha-blockers, 5-alpha reductase inhibitor within 12 months preceding irradiation, during and weeks following irradiation and before Succinate of Solifenacin treatment start,
* Contraindication of Succinate of Solifenacin
* Hypersensitivity or allergy to Solifenacin succinate or to any other antimuscarinic agent,
* Specific precautions of use for patients having decompensated urinary tract obstruction at risk of urinary retention, vegetative neuropathy, long QT syndrome and an hypokaliemia, history of long QT or patients at risk of QT prolongation, obstructive gastrointestinal disorders.
* Patients treated with oral biphosphonates, drugs that cause QT prolongation or by substrates having affinity for CYP3A4 isoenzyme as verapamil and Diltiazem, or treated with CYP3A4 inductors as rifampicin, phenytoin, carbamazepine
* Galactose hereditary intolerance, lactase deficiency or a malabsorption syndrome of glucose and galactose.
* Patient enable to follow study medical care for family, social, geographical or psychological reasons.
* Participation to another clinical study on urinary toxicity and/or molecule that could modify this toxicity and its evolution.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No